Shanghai Haixin Group Co Ltd B Total Liabilities

Latest as of June 2026: $1.01 Billion USD

Shanghai Haixin Group Co Ltd B total liabilities. Based on the latest financial reports, Shanghai Haixin Group Co Ltd B (900917) has total liabilities worth $1.01 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 900917 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Shanghai Haixin Group Co Ltd B (2015–2025)

Total liabilities of Shanghai Haixin Group Co Ltd B from 2015 to 2025. This chart illustrates how Shanghai Haixin Group Co Ltd B's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Shanghai Haixin Group Co Ltd B to see how much of total assets are deployed in long-term investments.

Shanghai Haixin Group Co Ltd B Competitors by Total Liabilities

The table below lists competitors of Shanghai Haixin Group Co Ltd B ranked by their total liabilities.

Company Country Total Liabilities
Definitive Healthcare Corp
NASDAQ:DH
USA $356.50 Million
PT Mandiri Herindo Adiperkasa Tbk
JK:MAHA
Indonesia Rp994.58 Billion
Endeavour Mining Corp
LSE:EDV
UK GBX2.79 Billion
Kt Skylife
KO:053210
Korea ₩415.51 Billion
Servotronics Inc
NYSE MKT:SVT
USA $13.01 Million
Southern Hydropower JSC
VN:SHP
Vietnam ₫64.87 Billion
Lalin Property Public Company Limited
BK:LALIN
Thailand ฿8.19 Billion
Sound Point Meridian Capital, Inc.
NYSE:SPMC
USA $175.83 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Shanghai Haixin Group Co Ltd B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shanghai Haixin Group Co Ltd B balance sheet assets.

Liquidity & Leverage Metrics

Shanghai Haixin Group Co Ltd B Total Liabilities Ratios Explained

Shanghai Haixin Group Co Ltd B total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 4.72 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.20 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.16 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shanghai Haixin Group Co Ltd B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shanghai Haixin Group Co Ltd B (2015–2025)

The table below shows the annual total liabilities of Shanghai Haixin Group Co Ltd B from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 $925.47 Million +11.44%
2024-12-31 $830.43 Million +7.11%
2023-12-31 $775.29 Million -14.92%
2022-12-31 $911.22 Million -12.62%
2021-12-31 $1.04 Billion -16.28%
2020-12-31 $1.25 Billion +12.21%
2019-12-31 $1.11 Billion +25.54%
2018-12-31 $884.20 Million -6.16%
2017-12-31 $942.20 Million -13.48%
2016-12-31 $1.09 Billion -12.26%
2015-12-31 $1.24 Billion --

About Shanghai Haixin Group Co Ltd B

SHG:900917 China Conglomerates
Market Cap
$120.03 Million
Market Cap Rank
#18260 Global
#4663 in China
Share Price
$0.26
Change (1 day)
-0.78%
52-Week Range
$0.24 - $0.29
All Time High
$0.82
About

Shanghai Haixin Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in China and internationally. It is also involved in leasing of industrial park properties, financial investment and commodity trading, as well as production and sales of chemical drugs through its sales platform or local distributors; and research and development, production, and sales of plush fabrics… Read more